The purpose of this study is to examine:

• The short- and long-term effectiveness and tolerability of quetiapine XR for the treatment of social anxiety disorder (SAD)
• The continuation effects of quetiapine XR in preventing SAD relapse

Eligibility

We are looking for subjects 18-65 years old.

Requirements

The study consists of eight weeks of open-label treatment with quetiapine XR (50-400 mg/day). Those who show a minimal improvement will go into a 12-week period with either quetiapinr XR or placebo.

There are total of 10 visits to Duke.

Compensation

Subjects will be compensated up to $270 after the completion of the study.